- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00735761
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of this study was to evaluate the episode duration of a herpes labialis recurrence, following a 5-day treatment with 5-time daily topical administration of ME-609 or acyclovir cream, in immunocompromised adults, 18 years and older.
This interim report summarizes the results for short-term observations, i.e., during the initial study recurrence. A final study report will be prepared when the long-term follow-up is completed.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of recurrent herpes labialis with at least two recurrences during the twelve months prior to the study.
- Stable HIV infection
- CD4+ T-cell count 100 to 500/mm3
Exclusion Criteria:
- Systemic treatment with other antiviral agent or corticosteroids within two weeks prior to and during the treatment period, except for antiretroviral treatment in HIV subjects
- Topical treatment with other antiviral agent or corticosteroids within in or around the oral area within two weeks prior to study drug administration
- Significant skin condition that occur in the area typically affected by herpes recurrences
- Nursing or pregnancy
- Concurrent cancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
ME-609 (5% acyclovir and 1% hydrocortisone)
|
Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
|
Active Comparator: 2
Acyclovir in ME-609 vehicle (5% acyclovir)
|
Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary variable was episode duration, measured from the start of treatment until loss of hard crust for an ulcerative recurrence and from the start of treatment to time of no signs or symptoms for a non-ulcerative recurrence (Investigator-assessed).
Time Frame: from start of treatment until loss of hard crust
|
from start of treatment until loss of hard crust
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary variable was the time to next recurrence measured from the start of the study recurrence until the start of the next recurrence.
Time Frame: Start of recurrence until start of next recurrence
|
Start of recurrence until start of next recurrence
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anders Sönnerborg, MD PhD Prof., Clinical Virology, F68, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Stomatognathic Diseases
- Mouth Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Herpesviridae Infections
- Lip Diseases
- Herpes Simplex
- Herpes Labialis
- Anti-Infective Agents
- Antiviral Agents
- Anti-Inflammatory Agents
- Hydrocortisone
- Acyclovir
Other Study ID Numbers
- 609-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Labialis
-
BayerActive, not recruitingRecurrent Herpes LabialisUnited States
-
Topical RemedyBenu BioPharma, LLCCompletedRecurrent Herpes LabialisUnited States
-
NanoBio CorporationCompletedRecurrent Herpes LabialisUnited States
-
Southern California University of Health SciencesCompletedHerpes SimplexUnited States
-
Leciel BonoRecruitingHSV-1 | Herpes Simplex Labialis | Virus | Herpes Simplex 1United States
-
Topical RemedyBenu BioPharma, LLC; Accelovance; Optimal ResearchCompletedRecurrent Herpes LabialisUnited States
-
University of ZurichDevirex AGCompleted
-
NovartisCompleted
-
Hadassah Medical OrganizationUnknownReccurent Herpes Labialis
-
Laboratoire Boreaderme Inc.Ecogene 21Unknown
Clinical Trials on ME-609
-
MedivirCompleted
-
MedivirCompletedHerpes LabialisUnited States
-
MedivirCompleted
-
TakedaAvailableHunter SyndromeUnited States, Australia, Mexico, Spain, United Kingdom
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Completed
-
AmgenCompletedNon-alcoholic Fatty Liver DiseaseUnited States
-
Foghorn Therapeutics Inc.Active, not recruitingAdvanced Synovial SarcomaUnited States, Spain, France, Italy
-
University of OxfordCompleted
-
Shanghai Jiao Tong University School of MedicineCompleted
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileCompleted